NASDAQ:KTWO - Nasdaq - US48273J1079
Medical-technology giants have announced nearly $5 billion in acquisitions this year amid medtech innovation in heart valves and robotic surgery.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 10) Merck & Co., Inc. (...
KTWO – Announces receipt of FDA clearance including surgical guidance that enhances MESA platform using patient-specific rods and rails.
Medtech stock Edwards Lifesciences broke out in high volume Monday on a rumor that Dow Jones component Johnson & Johnson could be interested in buying it.
Top Upgrades DA Davidson upgraded Avon Products, Inc. (NYSE: AVP) from Neutral to Buy. Avon Products shares rose 3.28 percent to $2.52 in pre-market trading. B. Riley FBR...
Stryker is spending $190 million to buy medical-technology firm Invuity and add on potentially $1.25 billion in market opportunity, an analyst said Tuesday.
Stryker is spending $190 million to buy medical-technology firm Invuity and add on potentially $1.25 billion in market opportunity, an analyst said Tuesday.
Stryker is paying $1.4 billion to acquire K2M Group Holdings and solve its "problem child" unit of spinal products, an analyst said Thursday. The medtech firms' deal is expected to close in the fourth quarter.
KTWO – JMP Securities downgrades to Market Perform from Outperform. Stock price at the time of this analyst call was $27.39.
In a report released today, Michael Matson from Needham downgraded K2M Group Holdings (NASDAQ: KTWO) to Hold. The company’s shares opened today at $27.41, close to its 52-week high of $27.47. Matson observed: “SYK announced an agreement to acquire KTWO for $27.50 per share (a 26% premium to KTWO’s closing price on 8/29/18) or ~$1.4B
Mentions: SYK
Stryker is buying the medical device maker. Here's what investors need to know.
Mentions: SYK
KTWO – Cantor Fitzgerald reiterates Buy rating, $28 PT. This price target represents a 28.32% upside over the stock’s previous closing price of $21.82.
Mentions: SYK
In a report released today, Craig Bijou from Cantor Fitzgerald maintained a Buy rating on K2M Group Holdings (NASDAQ: KTWO), with a price target of $28. The company’s shares closed yesterday at $21.82. Bijou observed: “We believe that KTWO’s outperformance in the US market over the last two years has been underappreciated. We think US
KTWO – K2M Group to be acquired by Stryker Corporation for $27.50/share in cash, or approximately $1.4 bln.